Merial Sas

Other

Merial Limited

Cerebus Biologicals Inc.

University of Saskatchewan

The Queen's University of Belfast

Eaton, Kathryn

John Ellis

Brian Martin Meehan

Catherine Elisabeth Charreyre

John R Harding

Gilles Emile Chappuis

Gordon Moore Allan

Francis McNeilly

Deborah Haines

Lori Hassard

Edward Clark

Andrew A Potter

Lorne A Babiuk

Philip J Willson

Li Wang

George Krakowka

Jean-Christophe Francis Audonnet

Jean-ChrJistophe Francis Audonnet

George Steve Krakowka

Gordon Allan Moore

Joel Flores

Kathryn Eaton

Kathyrn Eaton

John Harding

Gordon Allan

Brian Meehan

Déborah Haines

Kathym Eaton

The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.

Postweaning multisystemic wasting syndrome and porcine circovirus from pigs

Compositions and methods for treating, preventing and diagnosinginfection are disclosed. The methods use proteins and/or nucleic acids derived from, a new pathogen isolated from swine. In addition, porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused bypathogens, such asandare described, as well as methods of identifying vaccines and compounds for treating and/or preventinginfection using the animal models. Also described are methods of preventinginfection in swine, such as infection caused by, using immunogenic proteins and nucleic acids derived frompathogens, such as

[object Object]

Provided is a method for reducing viral load of porcine circovirus type 2 (PCV-2) in a pig by inducing an immune response against PCV-2 through the administration of an immunogenic composition comprising a PCV-2 antigen. A preferred antigen is a vector containing a PCV-2 nucleotide sequence. In a particularly preferred embodiment, the PCV-2 nucleotide sequence is ORF4, ORF13, or ORF4 and ORF13. In some embodiments, the immunogenic composition includes one or more additional pig pathogens.

Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2

The invention relates to new porcine circovirus strains isolated from pulmonary or ganglionic samples obtained from farms affected by the post-weaning multisystemic wasting syndrome (PMWS). It relates to purified preparations of these strains, conventional attenuated or inactivated vaccines, recombinant live vaccines, plasmid vaccines and subunit vaccines, as well as reagents and diagnostic methods. It also relates to the DNA fragments which can be used for the production of subunits in an in vitro expression vector or as sequences to be integrated into a virus or plasmid type in vivo expression vector.

Porcine circoviruses, vaccines and diagnostic reagents

The invention relates to antigenic preparations and vaccines directed against the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type II, and at least one porcine parvovirus antigen.

Porcine circovirus and parvovirus vaccine

Porcine circovirus-2 (PCV-2) is a recently identified agent wherein the potential spectrum of PCV-2-associated disease has been expanded by evidence of vertical and sexual transmission and associated reproductive failure in swine populations. PCV-2 was isolated from a litter of aborted piglets from a farm experiencing late term abortions and stillbirths. Severe, diffuse myocarditis was present in one piglet associated with extensive immunohistochemical staining for PCV-2 antigen. Variable amounts of PCV-2 antigen were also present in liver, lung and kidney of multiple fetuses. Inoculation of female pigs with a composition including an immunogen from PCV-2 or an epitope of interest from such an immunogen or with a vector expressing such an immunogen or epitope of interest prior to breeding, such as within the first five weeks of life, or prior to the perinatal period, or repeatedly over a lifetime, or during pregnancy, such as between the 6 and 8 and/or the 10 and 13 weeks of gestation, can prevent myocarditis, abortion and intrauterine infection associated with porcine circovirus-2. In addition, innoculation of male and/or female pigs with the aforementioned compositions can be carried out to prevent transmission of PCV-2 from male to female (or vice versa) during mating. Thus, the invention involves methods and compositions for preventing myocarditis, abortion and intrauterine infection associated with porcine circovirus-2.

Reduction of porcine circovirus-2 viral load with inactivated PCV-2

Porcine circoviruses vaccines diagnostic reagents

Porcine circovirus vaccine and diagnostics reagents

Growing community of inventors

Saskatoon, Canada

John Ellis